Treatment costs of attention deficit hyperactivity disorder in Germany

Braun S, Zeidler J, Linder R, Engel S, Verheyen F, Greiner W (2013)
The European Journal Of Health Economics 14(6): 939-945.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor*in
Braun, Sebastian; Zeidler, Jan; Linder, Roland; Engel, Susanne; Verheyen, Frank; Greiner, WolfgangUniBi
Abstract / Bemerkung
Attention deficit hyperactivity disorder (ADHD) is one of the most common behavioural disorders among children and adolescents. The number of patients as well as prescriptions to treat this disease has continuously increased over the past few years. The aim of the present study was to analyse the costs for treating ADHD patients from the perspective of a major German health insurance fund. Anonymised administrative claims data were available for the study. All services reimbursed by the health fund for the selected ADHD patients were recorded. Apart from the resource use attributed directly to ADHD, co-morbidities as well as incremental costs were described based on a control group design. A total of 30,264 ADHD patients were diagnosed in 2008. The total costs for these patients were a,not sign3,888, and the incremental costs were a,not sign2,902. The largest proportions of incremental costs were due to therapeutic devices and remedies like occupational therapy amounting to a,not sign1,270. Proportionate costs of a,not sign263 have been settled for pharmacotherapy with Methylphenidate and Atomoxetine. However, 41 % of the patients were not treated with ADHD-related pharmaceuticals. ADHD costs are relevant from health insurance perspective. The expenses for occupational therapy constitute the cost driver. Compared to the findings of studies from the United States and contrarily to the backdrop of public discussions about considerably increased prescriptions of ADHD-specific drugs, the significantly higher additional expenses for occupational therapy services are impressing. This kind of therapy is internationally rather unknown and is therefore not acknowledged as a therapeutic standard.
Stichworte
Costs; Germany; Social health insurance fund; Claims data; ADHD
Erscheinungsjahr
2013
Zeitschriftentitel
The European Journal Of Health Economics
Band
14
Ausgabe
6
Seite(n)
939-945
ISSN
1618-7598
eISSN
1618-7601
Page URI
https://pub.uni-bielefeld.de/record/2638454

Zitieren

Braun S, Zeidler J, Linder R, Engel S, Verheyen F, Greiner W. Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics. 2013;14(6):939-945.
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., & Greiner, W. (2013). Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics, 14(6), 939-945. doi:10.1007/s10198-012-0440-5
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., and Greiner, W. (2013). Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics 14, 939-945.
Braun, S., et al., 2013. Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics, 14(6), p 939-945.
S. Braun, et al., “Treatment costs of attention deficit hyperactivity disorder in Germany”, The European Journal Of Health Economics, vol. 14, 2013, pp. 939-945.
Braun, S., Zeidler, J., Linder, R., Engel, S., Verheyen, F., Greiner, W.: Treatment costs of attention deficit hyperactivity disorder in Germany. The European Journal Of Health Economics. 14, 939-945 (2013).
Braun, Sebastian, Zeidler, Jan, Linder, Roland, Engel, Susanne, Verheyen, Frank, and Greiner, Wolfgang. “Treatment costs of attention deficit hyperactivity disorder in Germany”. The European Journal Of Health Economics 14.6 (2013): 939-945.

10 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

[Economic evaluation of a manual-based, multimodal cognitive behavioural therapy for school avoiding children with psychiatric disorder].
Weschenfelder AK, Reissner V, Knollmann M, Hebebrand J, Wasem J, Neumann A., Z Kinder Jugendpsychiatr Psychother 46(1), 2018
PMID: 28117627
Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis.
Quintero J, Ramos-Quiroga JA, Sebastián JS, Montañés F, Fernández-Jaén A, Martínez-Raga J, Giral MG, Graell M, Mardomingo MJ, Soutullo C, Eiris J, Téllez M, Pamias M, Correas J, Sabaté J, García-Orti L, Alda JA., BMC Psychiatry 18(1), 2018
PMID: 29422022
Predictors of non-drug psychiatric/psychotherapeutic treatment in children and adolescents with mental or behavioural disorders.
Abbas S, Ihle P, Adler JB, Engel S, Günster C, Holtmann M, Kortevoss A, Linder R, Maier W, Lehmkuhl G, Schubert I., Eur Child Adolesc Psychiatry 26(4), 2017
PMID: 27628527
ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
Bachmann CJ, Philipsen A, Hoffmann F., Dtsch Arztebl Int 114(9), 2017
PMID: 28351466
Italian regional health service costs for diagnosis and 1-year treatment of ADHD in children and adolescents.
Casadei G, Cartabia M, Reale L, Costantino MA, Bonati M, Lombardy ADHD Group., Int J Ment Health Syst 11(), 2017
PMID: 28465719
The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs.
Maia CR, Stella SF, Mattos P, Polanczyk GV, Polanczyk CA, Rohde LA., Braz J Psychiatry 37(1), 2015
PMID: 25806553
Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis.
Klora M, Zeidler J, Linder R, Verheyen F, von der Schulenburg JM., Health Econ Rev 5(1), 2015
PMID: 26690366
[Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds].
Hoffmann F, Bachmann CJ., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(4), 2014
PMID: 24658675

26 References

Daten bereitgestellt von Europe PubMed Central.


AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years.
Wehmeier PM, Schacht A, Rothenberger A., Child Adolesc Psychiatry Ment Health 3(1), 2009
PMID: 19175910

O, 2007

W, 2007

AUTHOR UNKNOWN, 0

R, 2005

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.
Guevara J, Lozano P, Wickizer T, Mell L, Gephart H., Pediatrics 108(1), 2001
PMID: 11433056
Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder.
Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC., JAMA 285(1), 2001
PMID: 11150110
Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care.
Burd L, Klug MG, Coumbe MJ, Kerbeshian J., J. Child Neurol. 18(8), 2003
PMID: 13677583
Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A., J Am Acad Child Adolesc Psychiatry 42(12), 2003
PMID: 14627876
Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR., Curr Med Res Opin 21(2), 2005
PMID: 15801990
A review of the economic burden of ADHD.
Matza LS, Paramore C, Prasad M., Cost Eff Resour Alloc 3(), 2005
PMID: 15946385
Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity.
Ray GT, Levine P, Croen LA, Bokhari FA, Hu TW, Habel LA., Arch Pediatr Adolesc Med 160(10), 2006
PMID: 17018466
The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.
Pelham WE, Foster EM, Robb JA., J Pediatr Psychol 32(6), 2007
PMID: 17556402

AUTHOR UNKNOWN, 0
Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, Merkesdal S., Ann. Rheum. Dis. 62(6), 2003
PMID: 12759292
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M., Curr Med Res Opin 23(8), 2007
PMID: 17588306

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 23179162
PubMed | Europe PMC

Suchen in

Google Scholar